Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
About
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer”

3 trials

Filters

Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Status

Recruiting

Active, Not Recruiting

Not Yet Recruiting

Completed

Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Study completedNCT03711058

What this trial is testing

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Who this might be right for

Unresectable or Metastatic Microsatellite Stable (MSS) Solid TumorMicrosatellite Stable (MSS) Colon Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 48

Testing effectiveness (Phase 2)Active Not RecruitingNCT05609370

What this trial is testing

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Who this might be right for

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Testing effectiveness (Phase 2)WithdrawnNCT04119830

What this trial is testing

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Who this might be right for

Metastatic Colorectal AdenocarcinomaMicrosatellite StableMismatch Repair Proficient+10 more

Roswell Park Cancer Institute